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Abstract: The intractability of non-small cell lung cancer (NSCLC) to multimodality treatments
plays a large part in its extremely poor prognosis. Tumor necrosis factor-related apoptosisinducing ligand (TRAIL) is a promising cytokine for selective induction of apoptosis in cancer
cells; however, many NSCLC cell lines are resistant to TRAIL-induced apoptosis. The therapeutic effect can be restored by treatments combining TRAIL with chemotherapeutic agents.
Actinomycin D (ActD) can sensitize NSCLC cells to TRAIL-induced apoptosis by upregulation
of death receptor 4 (DR4) or 5 (DR5). However, the use of ActD has significant drawbacks due
to the side effects that result from its nonspecific biodistribution in vivo. In addition, the short
half-life of TRAIL in serum also limits the antitumor effect of treatments combining TRAIL and
ActD. In this study, we designed a combination treatment of long-circulating TRAIL liposomes
and ActD liposomes with the aim of resolving these problems. The combination of TRAIL
liposomes and ActD liposomes had a synergistic cytotoxic effect against A-549 cells. The
mechanism behind this combination treatment includes both increased expression of DR5 and
caspase activation. Moreover, systemic administration of the combination of TRAIL liposomes
and ActD liposomes suppressed both tumor formation and growth of established subcutaneous NSCLC xenografts in nude mice, inducing apoptosis without causing significant general
toxicity. These results provide preclinical proof-of-principle for a novel therapeutic strategy in
which TRAIL liposomes are safely combined with ActD liposomes.
Keywords: TRAIL, actinomycin D, liposomes, combination treatment, non-small cell lung
cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases of
lung cancer, which is the leading cause of cancer-related mortality in both men and
women throughout the world.1 Systemic chemotherapy has been considered the main
treatment for patients with early-stage NSCLC and part of the multimodal therapeutic
strategy for advanced-stage NSCLC.1,2 However, limited efficiency has been achieved
using chemotherapy. For example, the use of cytotoxic chemotherapy is associated with
a response rate of 20%–35% and a median survival time of 10–12 months in patients
with advanced NSCLC.3 This may be due to multidrug resistance in NSCLC. Several
resistance proteins, including P-glycoprotein, lung resistance protein, and multidrug
resistance-associated protein, have been proven to be simultaneously involved in
multidrug resistance of NSCLC.4 Therefore, there is a need to develop new anticancer
drugs and novel regimens capable of killing drug-resistant cells. Activation of the death
receptor pathway may provide a new modality in NSCLC treatment because of the
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ability of death receptors to induce apoptosis directly, thus
bypassing cellular drug resistance.5
A new candidate, tumor necrosis factor-related apoptosisinducing ligand (TRAIL), was identified as a powerful activator of programmed cell death or apoptosis in tumor cells that
also spared normal cells.6 TRAIL-induced apoptosis starts
with the binding of TRAIL to its cognate receptors DR4/5.
This binding leads to the formation of a death-inducing
signaling complex and subsequent activation of caspase-8.
Caspase-8 then activates downstream effector caspases, such
as caspase-3 and caspase-6, ultimately resulting in apoptosis.7
The selectivity of TRAIL for tumor cells has greatly spurred
research to explore its potential as an anticancer therapy.6,8,9
Although TRAIL is capable of inducing apoptosis in tumor
cells of diverse origin, recent studies have shown that the
majority of NSCLC lines, such as A-549 and H-522, are
resistant to the apoptotic effects of TRAIL, suggesting that
the use of TRAIL alone may be ineffective for NSCLC
therapy.10
There is increasing evidence that conventional chemotherapeutic agents upregulate death receptors in human
cancer cells. Therefore, it is possible that these conventional
chemotherapeutic drugs would enhance the cytotoxicity
of TRAIL. This approach might be useful in killing drugresistant cells. Importantly, a number of studies have shown
that treatments combining TRAIL with chemotherapy have
synergistic effects in several human tumor types and can
overcome resistance to either of the agents.10 Actinomycin D
(ActD), which is known to be a potent cytotoxic drug, can
sensitize pancreatic cancer and NSCLC cells to TRAILinduced apoptosis.11–13 However, the effectiveness of this
combination therapy on NSCLC xenograft model systems has
not been reported. Therefore, evaluation of the therapeutic
efficiency of combined ActD/TRAIL treatment on NSCLC
xenografts is necessary and feasible.
However, use of ActD has inevitable drawbacks due to
the side effects that result from its nonspecific biodistribution
in vivo. In addition, the short half-life of TRAIL in serum14
could also limit the antitumor effect of combined treatment
with TRAIL and ActD. In addition, some NSCLC cell lines
demonstrate cross-resistance to both TRAIL and ActD,
making combination therapies less effective.4,10
In recent years, liposomes have garnered attention for
cancer therapy because of their biocompatibility and versatility of formulation.15 Compared with free antitumor drugs,
drug-loaded long-circulating liposomes show a long circulation time in plasma, enhanced accumulation in tumor tissues,
and superior therapeutic activity. Our previous studies have
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indicated that the combination of TRAIL liposomes and
doxorubicin liposomes enhances antitumor effects.16,17 In
spite of these potential advantages, long-circulating liposomes have not been tested as a carrier for ActD, and the
clinical application of TRAIL liposomes combined with
ActD liposomes may result in enhanced antitumor effects.
The objective of the present study was to determine
whether ActD liposomes augment TRAIL liposome-induced
apoptosis of A-549, a NSCLC cell line, and to investigate
the underlying mechanisms by which this combined treatment achieves enhanced elimination of cancer cells. We
used the A-549 cell line as a multidrug resistant lung tumor
cell model because of the presence of ATP-binding cassette
efflux pumps such as P-glycoprotein, multidrug resistanceassociated protein, and breast cancer resistance protein in
A-549 cells.18

Materials and methods
Materials and animals
ActD was obtained from Life Science Co (Shanghai,
China). Human recombinant TRAIL was supplied by the
Shanghai Qiaer Biotechnology Co, Ltd, (Shanghai, China).
2-(4-Amidinophenyl)-6-indolecarbamidine dihydrochloride
(DAPI) and MTT were purchased from Sigma (St Louis,
MO). Antihuman death receptor 4 (DR4) and 5 (DR5) antibodies, human recombinant DR5/Fc and DR4/Fc chimera
proteins, monoclonal antihuman TRAILR1-phycoerytherin,
and monoclonal antihuman TRAILR2-phycoerytherin were
obtained from R & D Systems Inc (Minneapolis, MN).
Antibodies to caspase-9, caspase-3, and caspase-8 were
obtained from Bioworld Technology Inc (Louis Park, MN).
Egg yolk phosphatidylcholine (EPC) was purchased from QP
Corporation (Tokyo, Japan). Cholesterol (CHOL) and 1,2distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy
(polyethylene glycol)-2000] (DSPE-mPEG-2000) were
obtained from Avanti Polar Lipids Inc (Alabaster, AL). Fetal
bovine serum and Roswell Park Memorial Institute (RPMI)
1640 were ordered from Gibco (Carlsbad, CA). Doubledistilled water was purified using a Millipore Simplicity
System (Millipore, Bedford, MA). All other materials were
of analytical grade and used without further purification.
The NSCLC cell line A-549 was obtained from the
Institute of Biochemistry and Cell Biology at the Shanghai
Institutes for Biological Sciences of the Chinese Academy of
Sciences (Shanghai, China). The cells were cultured in RPMI
1640 supplemented with 100 U/mL penicillin, 100 µg/mL
streptomycin, and 10% fetal bovine serum at 37°C in a
humidified 5% CO2 atmosphere.
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BALB/c mice (BK Lab Animal Co Ltd, Shanghai, China)
were treated according to protocols approved by the Ethics
Committee of Fudan University.
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TRAIL stability study
TRAIL was dissolved in phosphate-buffered solution
(pH 7.4) at a concentration of 100 µg/mL, and then 3 mL
of 100 µg/mL TRAIL was divided into samples 1 (1 mL),
2 (1 mL), and 3 (1 mL). Sample 1 was kept at room temperature as a control. Sample 2 was incubated in a water bath at
40°C for one hour, while sample 3 was kept at 50°C for one
hour. The cytotoxicity of each sample on A-549 cells was
then investigated using the MTT assay.

Preparation of ActD liposomes
The formulation of ActD liposomes was as follows:
EPC:CHOL:DSPE-mPEG-2000:ActD = 20:5:5:0.8 (w/w).
Briefly, ActD (0.8 mg) and lipids with the compositions
described above were dissolved in 6 mL of chloroform.
Following the addition of 4 mL of phosphate-buffered solution
(pH 7.4), a dry lipid film prepared from the mixture was vortexed for 5 minutes and then suspended for 4 hours. The liposomal suspension was then subjected to a sonication procedure
of 200 W for 20 seconds (intermittent). Large liposomes and
nonentrapped ActD particles were removed by three passes
through polycarbonate membrane filters with 0.22 µm pores.
The ActD liposomes were stored at 4°C until use.
The TRAIL liposomes were prepared as previously
reported.17 The lipid composition of the TRAIL liposomes
was as follows: EPC:CHOL:DSPE-mPEG-2000 = 65:15:15
(w/w). Briefly, lipids with the compositions described above
(total weight 95 mg) were dissolved in chloroform, dried into
a thin film in a round bottom flask on a rotary evaporator
under reduced pressure at 40°C. The dried lipid film was
rehydrated in 4 mL of 5 mg/ml TRAIL solution adjusted to
pH 7.4 and 290 osmolarity with NaCl at room temperature,
sonicated in an ice bath, and then subsequently extruded three
times through a 0.22 µm pore size polycarbonate filter. The
resulting liposomes were filtered through sepharose (CL-4B)
to remove nonentrapped TRAIL.

Characterization of liposomes
Liposome size was determined by dynamic light scattering
using a zeta potential/particle sizer Nicomp 380 ZLS (Particle
Sizing Systems, Santa Barbara, CA). In addition, liposomes
were observed using transmission electron microscopy
(H-600, Hitachi, Japan) following negative staining with 1%
sodium phosphotungstate solution for 2 minutes.

International Journal of Nanomedicine 2012:7
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The concentration of ActD within the liposomes was
measured by ultraviolet absorbance at 458 nm (UV-2401PC,
Shimadzu, Tokyo, Japan). Briefly, 2 mL of the filtered ActD
liposomes or nonfiltered ActD liposomes was dissolved in
7 mL ethanol, and the final volume was adjusted to 10 mL
with ethanol. After vortexing for 10 minutes, this suspension was filtered with polycarbonate membrane filters with
0.22 µm pores to remove undissolved materials. The ultraviolet absorbance of each sample was then measured and
the concentration of ActD was determined accordingly.
The loading efficiency was calculated using the following
equation:
Loading efficiency (%) = Fi/Ft × 100

where Fi is the concentration of ActD loaded in the liposomes after their dissolution in ethanol and Ft is the initial
concentration of ActD.
In contrast, nonentrapped TRAIL was tested using the
Coomassie Brilliant Blue G-250 binding assay.19 Briefly,
the nonentrapped TRAIL was collected by passing TRAIL
liposomes through sepharose; 2.5 mL of Coomassie Brilliant
Blue G-250 (0.5 mg/mL) was then added to 1 mL of the collected TRAIL solution. A series of concentrations of TRAIL
(2–80 µg/mL) was used as a control. The ultraviolet A450
and A590 of each sample were measured within 20 minutes.
The concentration of TRAIL was determined by A590/A450.
The loading efficiency of TRAIL was calculated using the
following equation:
Loading efficiency (%) = (Ft - Fi)/Ft × 100

(2)

where Fi is the concentration of nonentrapped TRAIL after
the liposomes were passed through the sepharose column
and Ft is the initial concentration of TRAIL.
The release of TRAIL or ActD from liposomes was
examined by incubating 1 mL of liposomes in a dialysis bag
immersed in 20 mL of phosphate-buffered solution (pH 7.4).
The entire system was stirred at 37°C. The amount of TRAIL
and ActD released at each time point was determined using
Coomassie Brilliant Blue G-250 binding and ultraviolet
analysis, respectively.

Nuclear staining

A-549 cells were placed in six-well culture plates (5 × 105/well)
and incubated for about 12 hours. The cells were then treated
for 12 hours with TRAIL liposomes alone (100 ng/mL), ActD
liposomes alone (1 µg/mL) or both. The culture medium
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was then removed and cells were washed with phosphatebuffered solution twice and fixed with 3.7% paraformaldehyde in phosphate-buffered solution for 10 minutes at room
temperature. Fixed cells were washed three times with phosphate-buffered solution and stained with 0.5 µg/mL DAPI
solution for 15 minutes in the dark at room temperature.
Finally, cells were observed via fluorescence microscopy
(Leitz, Germany).

Cytotoxicity assay
Cytotoxicity was evaluated using the MTT survival assay.
Briefly, A-549 cells were plated at 10,000 cells/well in
96-well microtiter plates overnight. Cells were then treated
with 100 µL fresh medium containing ActD liposomes alone,
TRAIL liposomes alone, or both agents and cultured for
24 hours. Following an additional 4 hours of culture with
0.5 mg/mL MTT, samples were analyzed using a microplate
reader (Multiskan MK3, Thermo Scientific, MA). The effects
of the treatments were expressed as a percentage of growth
inhibition using untreated cells as the noninhibited control.

Western blot analysis
Preparation of whole cell protein lysates and Western blot
analysis were performed as previously described.20,21 In brief,
whole cell protein lysates were electrophoresed through
denaturing polyacrylamide slab gels, and the protein bands
were transferred to a polyvinylidene fluoride membrane.
The membrane was then probed with primary antibodies to
caspase-9 (1:1000), caspase-8 (1:1000), caspase-3 (1:1000),
DR5 (1:1000), DR4 (1:1000), and GAPDH (1:1000) from
Sigma, St Louis, MO. Primary antibodies were detected using
goat antimouse or antirabbit horseradish peroxidase-link
secondary antibodies (1:10,000). After washing, the ECL
chemical reagents were added to the membrane and chemiluminescence was detected by exposure of the membranes to
Kodak-X-Omat films for 30 seconds to 10 minutes.

Membrane expression of DR4 and DR5
Cells were analyzed for surface expression of DR4 and DR5
by direct staining with monoclonal antihuman TRAILR1phycoerytherin and monoclonal anti-human TRAILR2phycoerytherin. Briefly, cells were seeded at 1 × 105 cells/
well in 24-well plates overnight. Cells were then treated
with fresh medium containing ActD liposomes and further cultured for 8 hours. Cells were stained with 0.5 mL
phosphate-buffered solution containing 1 µg/mL of monoclonal antihuman TRAILR1-phycoerytherin or monoclonal
antihuman TRAILR2-phycoerytherin antibody at 4°C for
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30–45 minutes. After washing with phosphate-buffered
solution, the expression of DR4 or DR5 was analyzed using
fluorescence microscopy (Leitz, Germany).

Antitumor activity of ActD and TRAIL
liposome combination treatment

A-549 cells (2 × 106) were suspended in 0.1 mL phosphatebuffered solution and injected subcutaneously into the right
flank of BALB-C strain female nude mice 6–8 weeks of age.
For the treatment of the established xenografts, the tumors
were permitted to establish and grow for 20 days (tumor
volume, 50–100 mm3). After tumor formation, the mice
were divided into seven treatment groups (five mice/group)
and received injection of the following treatments via tail
vein: control (pH 7.4 phosphate-buffered solution); TRAIL
0.6 mg/kg; ActD 0.06 mg/kg; TRAIL 0.6 mg/kg + ActD
0.06 mg/kg, pH 7.4 phosphate-buffered solution; TRAIL
liposomes 0.6 mg/kg; ActD liposomes 0.06 mg/kg; TRAIL
liposomes 0.6 mg/kg + ActD liposomes 0.06 mg/kg. The
administration of drugs was carried out daily for 12 days.
Tumor size was measured with calipers every day. Tumor
volume was calculated using the following formula:
1/2 × (larger diameter) × (smaller diameter).2 Systemic
toxicity of the treatments was assessed by changes in mouse
body weight.

Statistical analysis
Statistical evaluations of data were performed using the
unpaired Student’s t-test and one-way analysis of variance.
Data were expressed as the mean ± standard deviation.
P , 0.05 was considered to be significant.

Results
TRAIL stability study
Although the sonication of liposomes was performed in an ice
bath, it is difficult to avoid heat buildup in a liposomal suspension. Because the activity of bioactive proteins can be easily
damaged by heat, we tested the susceptibility of TRAIL to
heat. As shown in Figure 1, heat treatment of TRAIL at 40°C
or 50°C for one hour had only a slight influence on TRAIL
bioactivity, suggesting that the bioactivity of TRAIL may
not be damaged by the sonication. In addition, the sonication
procedure did not significantly damage the TRAIL potent
(data not shown). These results indicated that the sonication procedure can be utilized in the preparation of TRAIL
liposomes. To the best of our knowledge, a stability study
of this type has not been previously reported.
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Figure 1 Effect of heat treatment on cytotoxicity of TRAIL to A-549 cells. Because A-549 cells are resistant to TRAIL, we added 1 µg/mL of actinomycin D to each
concentration of TRAIL as a sensitizer.
Abbreviation: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

Characteristics of liposomes
The physical properties of liposomes are listed in Table 1.
Dynamic light scattering results demonstrated that volumebased diameters of TRAIL liposomes and ActD liposomes
were around 110 nm, which is especially suitable for accumulation in tumor tissue due to enhanced permeation and retention.22 Importantly, the in vitro release results for the TRAIL
liposomes and ActD liposomes showed that the liposomes can
sustain ActD and TRAIL release, suggesting the possibility of
a prolonged circulation time for both drugs. We also examined
the shape and size of these liposomes under a transmission
electron microscope (Figure 2). Most TRAIL and ActD liposomes were spherical and had a regular shape.

Cytotoxicity assay
For qualitative assessment of apoptosis induced by TRAIL
liposomes alone, ActD liposomes alone, or both agents,
we analyzed chromatin condensation and apoptotic bodies.
As shown in Figure 3A, treatment with TRAIL liposomes (100 ng/mL) alone for 12 hours did not induce any
morphological features or apoptotic bodies indicative of cell

death. Treatment with ActD liposomes (1.0 µg/mL) alone
induced only a slight increase in such morphological changes
and apoptotic bodies. In contrast, after combined treatment
with TRAIL liposomes and ActD liposomes, appearance of
apoptotic bodies was observed in A-549 cells. After washing
with phosphate-buffered solution and staining with DAPI, the
presence of apoptotic bodies and remarkably lower growth
density in cells treated with the combination treatment was
apparent (Figure 3B). This indicates that numerous dead
tumor cells produced by the combination treatment were
washed away by phosphate-buffered solution. These results
demonstrate that ActD liposomes significantly enhance apoptosis induced by TRAIL liposomes in A-549 cells.
To investigate further the cytotoxic effects of TRAIL liposomes and/or ActD liposomes, we treated A-549 cells with
the indicated agents and subjected them to the MTT assay.

Table 1 Physical properties of the liposomal formulations
Loading efficiency (%)
Particle size (nm)
Cumulative release
at 24 hours (%)

TRAIL liposomes

ActD liposomes

10.4 ± 3.9
115.6 ± 25.4
71.2 ± 4.3

92.0 ± 4.51
110.5 ± 45.3
62.9 ± 5.7

Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;
ActD, actinomycin D.

International Journal of Nanomedicine 2012:7

Figure 2 Transmission electron micrographs of liposomes. TRAIL liposomes (left),
ActD liposomes (right).
Note: Bar = 100 nm.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;
ActD, actinomycin D.
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Figure 3 Induction of apoptosis in A-549 cells by TRAIL liposomes and/or ActD liposomes. (A) Bar = 250 µm. (B) Bar = 250 µm.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ActD, actinomycin D; LPs, liposomes.

As shown in Figure 4A, neither TRAIL liposomes nor
ActD liposomes can significantly inhibit cell growth as
single agents; however, combined treatment with TRAIL
liposomes and ActD liposomes resulted in a sharp increase
in cell inhibition. This result is consistent with results
A

Inhibition (%)

reported elsewhere.10 Importantly, when A-549 cells were
treated with TRAIL liposomes (1.4–1000 ng/mL) and ActD
(1.4–1000 ng/mL) at a fixed ratio (1:1, w/w) for 24 hours,
the inhibition of cells significantly increased compared with
single treatment at each concentration point, confirming that

100
80
60
40

TRAIL
ActD
TRAIL + ActD
TRAIL-LPs
ActD-LPs
TRAIL-LPs + ActD-LPs

20
0

1.400

4.1
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Figure 4 (A) Effect of TRAIL liposomes and/or ActD liposomes on growth inhibition of A-549 cells. (B) Cell inhibition induced by forward or reverse sequential treatment
of TRAIL liposomes and ActD liposomes: 1, ActD liposome treatment for 24 hours; 2, TRAIL liposome treatment for 24 hours; 3, ActD liposome treatment for 8 hours →
TRAIL liposome treatment for 16 hours; 4, TRAIL liposome treatment for 16 hours → ActD liposome treatment for 8 hours.
Note: **P , 0.01.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ActD, actinomycin D; LPs, liposomes.
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cotreatment with TRAIL liposomes and ActD liposomes is
effective in inducing cell death. Similar results were also
found in the combined treatment with free TRAIL and ActD
for 24 hours in the same cell line.
Because A-549 cells are highly resistant to TRAILi nduced apoptosis, we next sought to test whether
A-549 cells can be inhibited by pretreatment with ActD
liposomes before treatment with TRAIL liposomes.
Interestingly, if A-549 cells were pretreated with ActD
liposomes alone for 8 hours followed by treatment with
TRAIL liposomes for an additional 16 hours, effective
cell inhibition was also observed (Figure 4B). To examine
this synergistic interaction, the reverse sequence of drug
exposure was used, where cells were pretreated with TRAIL
liposomes for 16 hours, followed by treatment with ActD
liposomes for an additional 8 hours. This reverse sequence
of drug exposure resulted in significantly less cell inhibition
than the sequential treatment of cells with ActD liposomes
followed by TRAIL liposomes. Taken together, these results
indicate that sequential treatment with ActD liposomes
followed by TRAIL liposomes or synchronous treatment
of ActD liposomes and TRAIL liposomes can be used to
kill A-549 cells.

TRAIL and actinomycin D liposomes

for the failure to form a TRAIL death-inducing signaling
complex and later steps in apoptosis.
In light of the studies cited above, it is important to know
whether ActD liposome treatment leads to regulation of DR4
and DR5 expression on the cell surface. We therefore evaluated TRAIL receptor expression on the surface of A-549 cells
at 4, 8, and 12 hours after treatment with ActD liposomes.
Western blot analysis showed that the basal level of expression of both DR4 and DR5 increased significantly after
treatment with ActD liposomes (Figure 5A). The increased
expression of DR4 and DR5 in A-549 cells may be at least
one of the reasons for the enhanced cytotoxicity of TRAIL
liposomes and ActD liposome combination treatment.

0h

4h

8h

12 h

A
DR4
DR5
GDAPH

B

ActD liposomes induce upregulation
of TRAIL receptor DR4 and DR5
It has been previously established that TRAIL induces
apoptosis through binding to cell receptors. Several TRAIL
receptors including DR4, DR5, decoy receptor 1 (DcR1),
2 (DcR2), and osteoprotegerin have been identified to date.
Both DR4 and DR5 contain a conserved death domain motif
and transduce TRAIL-mediated death signals to the intracellular apoptotic machinery. Unlike DR4 and DR5, DcR1 lacks
an intracellular domain, while DcR2 has a truncated death
domain. Thus, these two receptors act as decoy receptors
that antagonize TRAIL-induced apoptosis by competing
for ligand binding.23 Several mechanisms accounting for the
blocking of TRAIL-induced apoptosis have been reported
in individual cancer cell lines, including the simultaneous
expression of decoy receptors,24 overexpression of antiapoptotic molecules,25 and loss of caspase-8 expression.26
A number of studies have shown that anticancer drugs can
induce DR5 to sensitize cancer cells to TRAIL.27–30 It has also
been shown that DR4 can be transcriptionally induced by
chemotherapeutic drugs.31 However, another study showed
that sensitization can occur without increased TRAIL receptor expression.32 Regardless of total DR4 and DR5 protein
levels, their absence on the cell surface is sufficient to account

International Journal of Nanomedicine 2012:7
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Figure 5 (A) Effects of actinomycin D liposomes on DR4 and DR5 expression.
A-549 cells were treated with actinomycin D liposomes (0.125 µg/mL) for 4, 8, or
12 hours, respectively. Cell lysates were examined by Western blot. (B) Fluorescence
micrographs of DR4 and DR5 expression on untreated A-549 cells. (C) Fluorescence
micrographs of increased DR4 and DR5 expression on A-549 cells induced by
actinomycin D liposomes.
Note: Bar = 125 µm.
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The DR4 and DR5 upregulation induced by ActD liposomes and subsequent enhancement of TRAIL-mediated
cytotoxicity in A-549 cells may correlate with p53 status.
p53 acts as a transcription factor and induces apoptosis by
increasing gene expression of DR4 and DR5, resulting in
upregulation of DR4 and DR5 protein synthesis.28,33,34 Cells
treated with ActD liposomes expressed higher levels of both
DR4 and DR5 compared with untreated cells (Figure 5B
and C). In addition, the DR4 and DR5 were distributed
not only on the cell surface but also in the cytoplasm. It is
possible that ActD liposomes induce the redistribution
of DR4 and DR5 to lipid rafts at the plasma membrane,
favoring their aggregation.35 Although mRNA expression
of both DR4 and DR5 is present in many cancer cells, there
is no correlation between receptor expression levels and
the sensitivity of tumors to TRAIL. Recent studies have
suggested that the mRNA expression of TRAIL receptors
does not necessarily reflect their functional levels,36 so we
only investigated the expression of DR4 and DR5 proteins
in A-549 cells.

Contribution of DR4 and DR5
to apoptotic signaling
To investigate the relative contribution of DR4 or DR5 to the
transduction of the apoptotic signal in sensitive A-549 cells,
we selectively blocked each of the receptors with the corresponding chimeras (DR4/Fc and DR5/Fc, respectively).
As shown in Figures 6 and 7, only the DR5/Fc chimera
abolishes the combined effect of ActD liposomes and TRAIL
liposomes, indicating that the sensitization to apoptosis
induced by TRAIL liposomes is mediated by one but not
both upregulated receptors in A-549 cells.

A

B

TRAIL-LPs
ActD-LPs

+
+

+
+

+
+

DR4/Fc

−

+

−

DR5/Fc

−

−

+

Figure 6 Qualitative assessment of apoptosis induced by TRAIL liposomes, ActD
liposomes or both agents. (A) Bar = 250 µm. (B) Bar = 250 µm.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;
ActD, actinomycin D; LPs, liposomes.
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Figure 7 ActD liposomes enhance TRAIL liposome-induced cell inhibition through
upregulation of DR5. A-549 cells were treated with ActD liposomes (1 µg/mL)
and TRAIL liposomes (100 ng/mL) in the presence or absence of DR4/Fc chimera
(1000 ng/mL) or DR5/Fc chimera (1000 ng/mL).
Notes: **P , 0.01. Cell inhibition was tested using the MTT assay.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;
ActD, actinomycin D; LPs, liposomes.

TRAIL + ActD liposomes enhance
cytotoxicity via caspase activation
in A-549 cells
Cell apoptosis is primarily induced by two signaling pathways,
the intrinsic mitochondria-mediated pathway and the extrinsic death receptor-induced pathway, and cross-talk between
these pathways is mediated by the proapoptotic protein, Bid.29
Steps in the intrinsic pathway include cytochrome c release
from mitochondria and caspase 9 activation, followed by
activation of effector caspases, including caspase 3. Steps in
the extrinsic pathway include Fas-associated death domaindependent recruitment and activation of caspase 8, followed
by activation of the same effector caspases involved in the
intrinsic pathway.29 In previous studies, we determined that
DR5 upregulation plays a critical role in the sensitization of
A-549 cells mediated by ActD liposomes to TRAIL-induced
apoptosis. Next, we examined whether this sensitizing effect
was associated with activation of caspase.
Western blot results indicated that TRAIL liposomes
induced nearly no cleavage of caspase-3 or caspase-9, and
only slight cleavage of caspase-8 (Figure 8). In contrast, ActD
liposomes stimulated detectable processing of caspase-9,
whereas the combination treatment induced substantially
greater cleavage of caspase-8, caspase-9, and caspase-3,
therefore resulting in appearance of more active subunits
of caspase-3, caspase-8, and caspase-9. These observations
suggest that both the intrinsic mitochondria-mediated pathway and the extrinsic death receptor-induced pathway are
involved in the combined treatment.
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Figure 8 Effects of ActD liposomes or/and TRAIL liposomes on caspase activation.
A-549 cells were treated with ActD liposomes (1 µg/mL) and/or TRAIL liposomes
(100 ng/mL) for 12 hours.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;
ActD, actinomycin D; LPs, liposomes.
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Treatment of A-549 tumor xenografts
with TRAIL + ActD liposomes causes
growth suppression
We next tested the antitumor efficiency of the combination
treatment in vivo. Mice bearing subcutaneous A-549 tumor
xenografts were treated systemically with indicated agents
as described in the Materials and methods sections. The final
tumor volume of mice treated with the combination of TRAIL
liposomes and ActD liposomes was notably reduced. Furthermore, the tumor growth curve showed that tumor growth was
delayed most prominently in the group treated with TRAIL
liposomes and ActD liposomes (Figure 9A). The final weight
of tumor nodules in the group treated with TRAIL liposomes
and ActD liposomes was 392.2 ± 119.3 g (Table 2), which
was significantly lower than in the other groups. We were also
surprised to find no significant tumor inhibition in the other
groups, indicating the superiority of liposomal combination
treatment. In this study, body weight change was used as a
marker of the safety of the treatment. As shown in Figure 9B,
the body weight of mice treated with ActD, ActD liposomes,
ActD + TRAIL and ActD liposomes + TRAIL liposomes
recovered after cessation of drug treatment. In contrast,
the body weight of mice administered phosphate-buffered
solution, TRAIL, and TRAIL liposomes gradually increased
during the whole treatment period, again demonstrating the
minor side effects of TRAIL used alone.

Discussion
The high frequency of intrinsically TRAIL-resistant
NSCLC cell lines requires strategies to sensitize tumors for
TRAIL-induced apoptosis. Fortunately, the combined use of
TRAIL with chemotherapeutic drugs provides an option for
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Figure 9 (A) In vivo anticancer efficacy of different treatments in A-549 tumor
xenografts and (B) change in body weight as a function of time in subcutaneous
A-549 xenograft-bearing mice.
Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand;
ActD, actinomycin D; LPs, liposomes.

increasing antitumor activity in NSCLC models. The efficacy
of combined treatment with TRAIL and chemotherapy on
NSCLC has been demonstrated in a number of studies.10
However, the short half-life of TRAIL results in reduced
antitumor effects in vivo, which leads to the requirement for
larger amounts of TRAIL in clinical trials. Recent studies
have reported unanticipated side effects of TRAIL, including
proangiogenic-enhanced endothelial cell proliferation, migration, and cytoskeletal reorganization.37,38 In addition, a chief
concern with conventional chemotherapies is the inevitable
side effects from the nonspecific biodistribution of chemotherapeutic drugs. However, to date a strategy to improve
on the challenges posed by combination treatment has not
been reported in the published scientific literature. Here, we
used long-circulating liposomes as carriers to encapsulate
ActD and TRAIL with the aim of improving the therapeutic
efficiency and reducing the side effects. Our results indicate
that the combination of ActD liposomes with TRAIL liposomes has a better therapeutic effect against NSCLC than
free TRAIL and ActD combination treatment.
Long-circulating liposomes which are sterically stabilized
with surface-coupled polyethylene glycol and have approximately a 100 nm mean diameter can have an enhanced lifespan
in the circulation which is also conferred to their entrapped
therapeutic agents.39 In recent years, the development of
long-circulating liposomes has made it possible to prolong
the circulation time of anticancer drugs, target tumors, and
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Table 2 Final tumor weight (mg) of each mouse treated with different formulations
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TRAIL + ActD
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2
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4

5

Average

SD

P

Inhibition (%)

1371
1003
871
834
1205
687
525

1051
951
718
591
984
737
423

842
940
800
778
751
690
474

879
273
574
293
590
227
242

335
293
655
503
381
232
297

895.6
692.0
723.6
599.8
782.2
514.6
392.2

376.7
374.2
116.9
218.0
323.4
261.0
119.3

–
0.05
0.05
0.05
0.05
0.05
0.05

–
–
–
–
–
–
56.2

Abbreviations: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; ActD, actinomycin D; LPs, liposomes; SD, standard deviation.

reduce side effects. For example, doxorubicin is an areaunder-the-curve-dependent anticancer agent and is often used
for liposomal targeting to tumors. After encapsulation in longcirculating liposomes, liposomal doxorubicin can be delivered
to the extracellular space of tumor tissues. The doxorubicin
released in the extracellular space of tumors enhance its effectiveness and substantially increase the therapeutic index.22 In
this study, the synchronous accumulation of ActD liposomes
and TRAIL liposomes in tumors and subsequent drug release
in the extracellular space of tumors had a remarkable synergistic effect on the elimination of A-549 cells.
One phenomenon that should be noted is that no significant tumor inhibition was observed in mice treated with the
combination of free TRAIL and ActD (Table 2). As reported
elsewhere, in order to induce DR4 or DR5 in tumor tissue,
chemotherapeutic drugs were usually injected 24 hours prior
to administration of TRAIL.5,40,41 However, even with the
daily systemic injection of the combination of TRAIL and
ActD for 12 days, no promising antitumor efficiency was
observed in mice. One plausible explanation for this may be
that the short half-life of TRAIL allows insufficient time to
kill A-549 cells. It is also possible that ActD could not reach
a therapeutic concentration in tumor tissues. These results
again demonstrate the advantages of liposomes as drug carriers in cancer therapy.
TRAIL seems to require DR5 for maximal killing of
A-549 cells. This observation is consistent with previous
reports showing that DR5 plays a key role in inducing apoptosis in various types of cancer cells.21,33,42 Based on these
results, DR5 has been the primary target for development
of antibody therapies. There are currently five anti-DR5
antibody products, compared with one anti-DR4 product, in
clinical trials.36 The potential advantage of the DR5 antibody
is specific binding to the target receptor: the antibodies bind
selectively and with high affinity to their cognate receptor.43
In addition, the half-life of DR5, approximately 18–21 days,
is longer than that of TRAIL. However, the wide distribution
of DR5 in other tissues and lower accumulation of DR5 at the
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tumor site limits its efficiency. Therefore, we used liposomes
as a carrier to encapsulate TRAIL.
TRAIL-induced apoptosis uses the mitochondriamediated pathway. As we know, cross-talk between the
death receptor and mitochondrial pathway is mediated by
Bid. The cleavage of Bid activates the proapoptotic members,
Bax and Bak, resulting in release of cytochrome c from
the mitochondria.10 In contrast, Bcl-2 and Bcl-XL inhibit
chemotherapy or TRAIL-induced apoptosis by blocking
cytochrome c release.44 A-549 cells are resistant to TRAIL,
and this may indicate that the activation of caspase-8 in
A-549 cells by TRAIL alone is not sufficient to activate
downstream caspase and consequently induce apoptosis.
However, when A-549 cells were treated with the combination treatment of ActD liposomes and TRAIL liposomes,
mitochondria appear to amplify the apoptotic signals, leading
to more activation of caspase-9. Caspase-9, in turn, activates
downstream caspases and the cleavage of apoptotic substrates
that mediate dismantling of the cell, leading to more cleavage
of caspase-3 into active submits.5
In summary, we have developed a strategy that combines
ActD liposomes with TRAIL liposomes for the treatment of
NSCLC. We have shown that ActD liposomes act synergistically with TRAIL liposomes in inducing apoptosis in the
A-549 NSCLC cell line compared with treatment using ActD
liposomes or TRAIL liposomes alone. The enhanced apoptosis
is due to upregulation of DR5 induced by ActD liposomes in
A-549 cells. These studies provide a foundation for the development of combined treatment regimens that would enhance
the apoptotic response to TRAIL in cancer patients.
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